Key Takeaways:
Two law firms, The Schall Law Firm and Rosen Law Firm, have reminded investors of a class-action lawsuit against Medpace Holdings, Inc. (NASDAQ: MEDP) for alleged violations of federal securities laws during a 10-month period.
According to the lawsuits, throughout the Class Period, the defendants made false and/or misleading statements and failed to disclose material adverse facts about the true state of Medpace’s backlog cancellation rate. The complaints from the firms allege the company provided investors with overly positive growth expectations that it could not maintain.
The core of the allegations centers on Medpace's cancellation rates, which the company consistently described as "well behaved." Furthermore, the suit claims Medpace projected a 1.15 book-to-bill ratio that was unsustainable, creating a false impression of business strength. The lawsuits seek to recover damages for investors who purchased Medpace securities during the class period of April 22, 2025, and February 9, 2026. The deadline for investors to file as lead plaintiff is in early June 2026.
When the true details of the company's performance and cancellation rates entered the market, the lawsuit claims that investors suffered significant damages as the stock price corrected. The legal action argues that the company's public statements were materially false and misleading, leading to the inflation of the stock's value.
This legal action could expose Medpace to significant financial penalties and reputational damage, with investors watching for the company's official response. The next catalyst will be the court's decision on the certification of the class and the appointment of a lead plaintiff in June 2026.
This article is for informational purposes only and does not constitute investment advice.
